AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30936865
Drug: Dairy protein
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy protein supplement (6 grams/packet, twice per day for 8 weeks)
Trial: 30936865
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplement (6 grams/packet, twice per day for 8 weeks)
Trial: 27614706
Drug: Sequential Amplatz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Amplatz dilation
Trial: 21462258
Drug: Dopaminergic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medications
Trial: 16037752
Drug: Combined esterified
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) (EE/MT)
Trial: 16037752
Drug: Esterified estrogens
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogens (1.25 mg) alone (EE)
Trial: 12151959
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 without filgrastim
Trial: 12151959
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 days 1-3 and vinorelbine 25 mg/m2 days 1 and 8 with filgrastim
Trial: 10065780
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg/d; n = 14)
Trial: 10065780
Drug: CPA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA (25 mg plus ethinyl E2 (EE); n = 13)
Trial: 10065780
Drug: Flutamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (500 mg/d; n = 15)
Trial: 8640470
Drug: Non-suture method
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-suture method (Monsel's solution pack)
Trial: 6778456
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate in combination with low doses of lithium
Trial: 22894553
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg per day)
Trial: 11751182
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microg twice daily)
Trial: 10335001
Drug: Terbutaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (1 mg four times daily)
Trial: 7567317
Drug: Ceftibuten oral
RxNorm normalized name: ceftibuten Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten oral suspension at a dose of 9.0 mg/kg
Trial: 7567317
Drug: Ceftibuten oral
RxNorm normalized name: ceftibuten Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten oral suspension at doses of 4.5, 9.0, and 13.5 mg/kg
Trial: 7567317
Drug: Ceftibuten oral
RxNorm normalized name: ceftibuten Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten oral suspension
Trial: 31944893
Drug: Dental RECUR
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dental RECUR Brief Negotiated Interview for Oral Health (DR‐BNI)
Trial: 29197345
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg and Etoricoxib 120 mg
Trial: 19666639
Drug: Warfarin suspended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin suspended 3 days before surgery (Group 1)
Trial: 19666639
Drug: Warfarin suspended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin suspended <3 days or not at all (Group 2)
Trial: 19666639
Drug: Post-operation heparin
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operation heparin treatment
Trial: 19666639
Drug: Proposed protocol
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed protocol of perioperative anticoagulation (suspension of warfarin not <3 days with low-molecular-weight heparin bridging stopped 12 h before surgery)
Trial: 17203292
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg oral dose (PO)
Trial: 17203292
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg intravenous dose (IV)
Trial: 15213052
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (30 g ethanol/d for 28 days)
Trial: 29232214
Drug: Ultrasound-guided corticosteroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided corticosteroid injection above the median nerve
Trial: 29232214
Drug: Ultrasound-guided corticosteroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided corticosteroid injection below the median nerve
Trial: 10342407
Drug: Opioids (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (specific dosage and duration not mentioned)
Trial: 7739306
Drug: 585 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 585 nm flashlamp‐pumped pulsed‐dye laser treatment
Trial: 30927415
Drug: GnRHa trigger
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRHa trigger (buserelin 0.5 mg)
Trial: 26742509
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (PP) - 78‐234 mg, monthly injectable
Trial: 26742509
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (OA) - daily treatment
Trial: 22443173
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg per day)
Trial: 17919541
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir 10 mg once daily for 28 days
Trial: 10915082
Drug: 5-day oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day oral antibiotics
Trial: 8955760
Drug: Ibopamine 100
RxNorm normalized name: ibopamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 100 mg/day (group A)
Trial: 4000532
Drug: Tiropramide hydrochloride
RxNorm normalized name: tiropramide hydrochloride
DrugBank: Tiropramide (DB13091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiropramide hydrochloride 100 mg t.i.d. for 4 weeks
Trial: 31056840
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg danirixin hydrobromide
Trial: 31056840
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg danirixin hydrobromide
Trial: 31056840
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg danirixin hydrobromide
Trial: 31056840
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg danirixin hydrobromide (fed state - low-fat meal)
Trial: 19478822
Drug: Control (observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (observation or photodynamic therapy)
Trial: 17963760
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (ferrous sulfate tablet containing 50 mg elemental iron daily)
Trial: 14641799
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg) once daily for five consecutive days
Trial: 1593553
Drug: Daily vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vaginal suppositories of 10 mg of prostaglandin E2 (17 patients)
Trial: 1593553
Drug: Daily intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravesical solution of 50 micrograms of prostaglandin F2 alpha dissolved in 100 mL of normal saline (15 patients)
Trial: 1593553
Drug: Daily instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily instillation of 100 mL of saline (18 patients)
Trial: 27992112
Drug: BAY 94-9027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 94-9027 (every-5-days treatment)
Trial: 25530148
Drug: Treatment participants
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment participants (SPs)
Trial: 23387374
Drug: 2% tofacitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% tofacitinib ointment 1
Trial: 23387374
Drug: 2% tofacitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% tofacitinib ointment 2
Trial: 21429214
Drug: HDC/IL‐2 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC/IL‐2 treatment
Trial: 19320915
Drug: Risk-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-based oral health programme (OHP) targeting MS-positive subjects, involving repeated health education for caretakers and xylitol lozenges for children.
Trial: 19320915
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral health programme (control group).
Trial: 11240075
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg bid
Trial: 11240075
Drug: Dihydrocodeine 60
RxNorm normalized name: dihydrocodeine bitartrate 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 60 mg bid
Trial: 8033491
Drug: MK-0591 250
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 250 mg every morning for 10 days
Trial: 8033491
Drug: MK-0591 50
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 50 mg every morning for 10 days
Trial: 8033491
Drug: MK-0591 125
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 125 mg every morning for 10 days
Trial: 8033491
Drug: MK-0591 250
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 250 mg every 12 hours for 10 days
Trial: 8033491
Drug: MK-0591 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 (all doses)
Trial: 2567113
Drug: Dilevalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (200 to 1,600 mg once daily)
Trial: 2567113
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 to 400 mg once daily)
Trial: 23203241
Drug: Pregabalin, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin, starting at 150 mg/day, increasing to 300 or 450 mg/day
Trial: 15129933
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (3 x 10-g doses for 7 days)
Trial: 8967905
Drug: Trapidil 200
RxNorm normalized name: trapidil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil 200 mg t.i.d.
Trial: 9134282
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 20 mg t.i.d.
Trial: 7946235
Drug: Work therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work therapy stations
Trial: 3284488
Drug: Co-trimoxazole (CTZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (CTZ) 480 mg three times a day for 24 weeks
Trial: 3284488
Drug: Sulphapyridine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphapyridine 1.25 g a day
Trial: 25768057
Drug: Unilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral sequential endoscopic thoracic sympathectomy (S‐ETS)
Trial: 17179734
Drug: AST‐120 co‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST‐120 co‐administered with ongoing treatment
Trial: 17179734
Drug: Ongoing treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing treatments only (control group)
Trial: 10222447
Drug: pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole (40 mg)
Trial: 10222447
Drug: omeprazole MUPS
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole MUPS (20 mg)
Trial: 2331418
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine (10 micrograms) administered alone
Trial: 2331418
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine mixed with DTP vaccine
Trial: 2331418
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine administered alone
Trial: 27840069
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with the same first-line ACT
Trial: 27840069
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with the same ACT
Trial: 19291496
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) using the Modified Teaching Kids to Cope (MTKC)
Trial: 17091022
Drug: Medication Managers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Managers (MM)
Trial: 17091022
Drug: Medication Alarms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Alarms (ALR)
Trial: 15303639
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (3 microg/kg)
Trial: 15855578
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg nateglinide
Trial: 11739446
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg glyburide
Trial: 8101254
Drug: Sublingual oestradiol‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual oestradiol‐17 beta (1 mg)
Trial: 3305189
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, cytoxan, and prednisone (VCP)
Trial: 3305189
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with vincristine, rubidazone, araC, and prednisone (VRAP)
Trial: 21477047
Drug: Reinforcement-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement-based treatment (RBT)
Trial: 9315991
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg quazepam
Trial: 9315991
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg quazepam and 15 mg quazepam
Trial: 29303859
Drug: Bovine bone
RxNorm normalized name: bovine bone preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine bone xenograft granules (0.25 to 1 mm of size, 1 mL/vial) with a resorbable pericardium membrane
Trial: 19363850
Drug: Perindopril/indapamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril/indapamide combination
Trial: 19363850
Drug: Background antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background antihypertensive therapies
Trial: 17203670
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy interventions (personal care, information, prescription of assistive devices, planning of discharge, reporting to primary care or community care)
Trial: 17203670
Drug: No occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No occupational therapy interventions (control group)
Trial: 14601526
Drug: CpG‐7909 (ProMune)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG‐7909 (ProMune) in combination with rituximab (Rituxan) for non-Hodgkin's lymphoma
Trial: 14601526
Drug: CpG‐7909 (ProMune)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG‐7909 (ProMune) as a vaccine adjuvant
Trial: 1752712
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (650 mg ferrous sulfate; 130 mg elemental iron)
Trial: 7039147
Drug: Feprazone 600
RxNorm normalized name: feprazone
DrugBank: Feprazone (DB13364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feprazone 600 mg
Trial: 7039147
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg
Trial: 25838001
Drug: Treatment adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adherence (not using illicit opiates on top of prescribed opiates)
Trial: 23846250
Drug: Surfactant (calfactant)
RxNorm normalized name: Calfactant
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surfactant (calfactant) administration (30 mg/cm height, up to three doses)
Trial: 23846250
Drug: Surfactant (calfactant)
RxNorm normalized name: Calfactant
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surfactant (calfactant) administration
Trial: 17203469
Drug: Thienopyridine pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienopyridine pretreatment with loading dose (group 1)
Trial: 17203469
Drug: Thienopyridine pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienopyridine pretreatment without loading dose (group 2)
Trial: 7950223
Drug: Jian Pi
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jian Pi Ling (JPL) tablet with retention‐enema of Radix Sophorae Flavescentis and Flos Sophora (RSF‐FS) decoction
Trial: 28634365
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (clopidogrel plus aspirin) in patients with SBP ≥ 140 mmHg
Trial: 28634365
Drug: Clopidogrel-aspirin in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin in patients with DBP ≥ 90 mmHg
Trial: 28634365
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone in patients with SBP < 140 mmHg or DBP < 90 mmHg
Trial: 23562341
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A (CsA), treated twice a day for 6 weeks
Trial: 23562341
Drug: Placebo, treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, treated twice a day for 6 weeks
Trial: 18476292
Drug: Intermittent antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent antiretroviral therapy (ART; drug conservation [DC] group])
Trial: 16550574
Drug: Radiofrequency ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency ablation (RFA) combined with hepatic arterial infusion (HAI) chemotherapy (FUDR) for 6 months
Trial: 8634735
Drug: Single-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intramuscular (IM) ceftriaxone sodium
Trial: 8634735
Drug: 10-day oral
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day oral amoxicillin and clavulanate potassium
Trial: 2049686
Drug: Diltiazem monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem monotherapy
Trial: 2049686
Drug: Diltiazem-nitrate combination
RxNorm normalized name: organic nitrates in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem-nitrate combination
Trial: 2049686
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate added to either monotherapy
Trial: 6840166
Drug: Two well
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two well recognised treatment regimes
Trial: 29936600
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone (group G)
Trial: 22672578
Drug: Pulsed-dye laser
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-dye laser (PDL) treatment plus compression therapy (CT)
Trial: 20382711
Drug: Serum VEGF-D
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum VEGF-D levels > 800 pg/mL
Trial: 20382711
Drug: Serum VEGF-D
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum VEGF-D levels < 600 pg/mL
Trial: 20382711
Drug: VEGF-D level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF-D level > 600 pg/mL
Trial: 9820884
Drug: Fluoride-containing formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride-containing formulations (disodium monofluorophosphate and sodium fluoride)
Trial: 186090
Drug: Propranolol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.3 mg/kg)
Trial: 186090
Drug: Practolol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (1.0 mg/kg)